Cancer Clinical Trials

Biomarkers in Samples From Patients With Endometrial Cancer

This research study is studying biomarkers in samples from patients with endometrial cancer. Studying samples from patients with cancer in the laboratory may help doctors learn mor

Study number:: NCT01199250

Cohorts:: 1

Study phase:: N/A

Overall status:: Not yet recruiting

Study type:: Observational, Biomarker

Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers

This is a phase 1b multi-center, open-label study of HMBD-001 in combination with docetaxel with or without cetuximab in participants with locally advanced or metastatic squamous N

Study number:: NCT05910827

Cohorts:: 1

Study phase:: 1, 2

Overall status:: Recruiting

Study type:: Chemotherapy, Targeted therapy

Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma

This study is designed to investigate whether adjuvant radiochemotherapy after incomplete resection has a better survival than adjuvant radiotherapy for thymoma or thymic carcinoma.

Study number:: NCT02633514

Cohorts:: 1

Study phase:: 3

Overall status:: Recruiting

Study type:: Local/Regional therapies, Chemotherapy

Astrazeneca

Key trial

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investig

Study number:: NCT06103864

Cohorts:: 1

Study phase:: 3

Overall status:: Recruiting

Study type:: Immunotherapy, Targeted therapy

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

The primary objective of this study is to compare progression-free survival (PFS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who r

Study number:: NCT05920356

Cohorts:: 1

Study phase:: 3

Overall status:: Not yet recruiting

Study type:: Chemotherapy, Targeted therapy

Astrazeneca

Key trial

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer wit

Study number:: NCT05952557

Cohorts:: 1

Study phase:: 3

Overall status:: Recruiting

Study type:: Hormonal therapy

Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients

This is a single-centre, non-randomized, open label phase II trial to be conducted at the National Cancer Centre, Singapore (NCCS). Patients diagnosed with metastatic PDAC will be

Study number:: NCT05929885

Cohorts:: 1

Study phase:: 2

Overall status:: Not yet recruiting

Study type:: Any

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

This study will test the safety of the combination of ramucirumab and lorlatinib. The researchers will test one or two different doses of lorlatinib in combination with ramucirumab

Study number:: NCT06007937

Cohorts:: 1

Study phase:: 1, 2

Overall status:: Recruiting

Study type:: Biomarker, Targeted therapy

A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

The objective of this study is to determine overall response rate to combination of S-1 and Osimertinib in treatment-resistant EGFR mutant lung cancer.

Study number:: NCT05773092

Cohorts:: 1

Study phase:: 2

Overall status:: Not yet recruiting

Study type:: Targeted therapy

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placeb

Study number:: NCT05894239

Cohorts:: 1

Study phase:: 3

Overall status:: Recruiting

Study type:: Any